Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

IMiDs induce pleiotropic anti-cancer effects

IMiDs induce pleiotropic anti-cancer effects Lenalidomide (Revlimid®, also known as CC-5013) and pomalidomide (CC-4047) are IMiDs and chemical derivatives of thalidomide. Lenalidomide was introduced in 2004 and is currently approved for treatment of multiple myeloma and 5q-myelodysplastic syndromes (MDS). In addition, IMiDs are currently tested in a wide variety of haematological as well as solid tumours. IMiDs have three main anti-tumour properties, i.e. a direct anti-tumour effect, an inhibitory/modulatory effect on the tumour stroma/microenvironment supporting growth and survival of tumour cells including anti-angiogenic properties as well as a very potent immunomodulatory effect. The latter includes activation of T, NK and NKT cells as well as modulation of the function of mononuclear cells (DC and monocytes). However, the exact anti-cancer mechanisms of IMiDs in vivo remain elusive so far. This brief review will focus on the current concepts explaining the anti-cancer effects of IMiDs. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

IMiDs induce pleiotropic anti-cancer effects

Download PDF
3 pages

Loading next page...
 
/lp/springer-journals/imids-induce-pleiotropic-anti-cancer-effects-iY2oEUa5KL
Publisher
Springer Journals
Copyright
Copyright © 2009 by Springer-Verlag
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-009-0097-7
Publisher site
See Article on Publisher Site

Abstract

Lenalidomide (Revlimid®, also known as CC-5013) and pomalidomide (CC-4047) are IMiDs and chemical derivatives of thalidomide. Lenalidomide was introduced in 2004 and is currently approved for treatment of multiple myeloma and 5q-myelodysplastic syndromes (MDS). In addition, IMiDs are currently tested in a wide variety of haematological as well as solid tumours. IMiDs have three main anti-tumour properties, i.e. a direct anti-tumour effect, an inhibitory/modulatory effect on the tumour stroma/microenvironment supporting growth and survival of tumour cells including anti-angiogenic properties as well as a very potent immunomodulatory effect. The latter includes activation of T, NK and NKT cells as well as modulation of the function of mononuclear cells (DC and monocytes). However, the exact anti-cancer mechanisms of IMiDs in vivo remain elusive so far. This brief review will focus on the current concepts explaining the anti-cancer effects of IMiDs.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Jan 1, 2009

References

  • Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
    Dimopoulos, M; Spencer, A; Attal, M; Prince, HM; Harousseau, JL; Dmoszynska, A
  • Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion
    List, A; Dewald, G; Bennett, J; Giagounidis, A; Raza, A; Feldman, E
  • Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells
    Verhelle, D; Corral, LG; Wong, K; Mueller, JH; Moutouh-de Parseval, L; Jensen-Pergakes, K
  • Immunomodulatory drug costimulates T cells via the B7-CD28 pathway
    LeBlanc, R; Hideshima, T; Catley, LP; Shringarpure, R; Burger, R; Mitsiades, N
  • Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro
    Haslett, PA; Hanekom, WA; Muller, G; Kaplan, G
  • Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug
    Ramsay, AG; Johnson, AJ; Lee, AM; Gorgun, G; Le Dieu, R; Blum, W
  • Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications
    Chang, DH; Liu, N; Klimek, V; Hassoun, H; Mazumder, A; Nimer, SD
  • Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells
    Lapalombella, R; Yu, B; Triantafillou, G; Liu, Q; Butchar, JP; Lozanski, G
  • Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha
    Corral, LG; Haslett, PA; Muller, GW; Chen, R; Wong, LM; Ocampo, CJ
  • Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner
    Payvandi, F; Wu, L; Haley, M; Schafer, PH; Zhang, LH; Chen, RS
  • Identification of RPS14 as a 5q-syndrome gene by RNA interference screen
    Ebert, BL; Pretz, J; Bosco, J; Chang, CY; Tamayo, P; Galili, N
  • Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q-syndrome patients
    Pellagatti, A; Jadersten, M; Forsblom, AM; Cattan, H; Christensson, B; Emanuelsson, EK